Mather Group LLC. Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Mather Group LLC. grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 24.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,157 shares of the biopharmaceutical company’s stock after acquiring an additional 2,556 shares during the quarter. Mather Group LLC.’s holdings in Gilead Sciences were worth $964,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank purchased a new stake in Gilead Sciences in the 4th quarter worth about $1,301,624,000. The Manufacturers Life Insurance Company boosted its position in Gilead Sciences by 78.8% during the fourth quarter. The Manufacturers Life Insurance Company now owns 7,632,000 shares of the biopharmaceutical company’s stock worth $618,268,000 after purchasing an additional 3,362,505 shares during the period. Vanguard Group Inc. increased its stake in shares of Gilead Sciences by 2.6% in the first quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company’s stock worth $8,404,161,000 after purchasing an additional 2,910,147 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Gilead Sciences by 14.4% in the fourth quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock valued at $1,509,227,000 after purchasing an additional 2,350,550 shares during the period. Finally, Swedbank AB purchased a new stake in shares of Gilead Sciences during the 1st quarter valued at approximately $134,489,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on GILD. Cantor Fitzgerald lowered their target price on shares of Gilead Sciences from $75.00 to $70.00 and set a “neutral” rating on the stock in a report on Monday, July 22nd. Robert W. Baird reiterated a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research report on Thursday, June 20th. Oppenheimer restated an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a research report on Friday, April 19th. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective for the company in a report on Wednesday, April 24th. Finally, Morgan Stanley reduced their price target on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. Twelve investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $81.81.

Gilead Sciences Stock Up 0.8 %

Shares of GILD stock traded up $0.57 during midday trading on Wednesday, reaching $74.76. 766,424 shares of the stock were exchanged, compared to its average volume of 7,357,212. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $87.86. The firm has a market cap of $93.14 billion, a PE ratio of 206.08, a price-to-earnings-growth ratio of 3.37 and a beta of 0.18. The company’s 50 day moving average is $69.18 and its two-hundred day moving average is $70.49.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.